<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="alkap" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">alkap</book-part-id>
      <title-group>
        <title>Alkaptonuria</title>
        <alt-title alt-title-type="alt-title">Synonym: Alcaptonuria</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Introne</surname>
            <given-names>Wendy J</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Staff Clinician, Office of the Clinical Director, National Human Genome Research Institute<break/>National Institutes of Health<break/>Washington, DC</aff>
          <email>wintrone@nhgri.nih.gov</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gahl</surname>
            <given-names>William A</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Clinical Director, National Human Genome Research Institute<break/>National Institutes of Health<break/>Bethesda, Maryland</aff>
          <email>bgahl@helix.nih.gov</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>9</day>
          <month>5</month>
          <year>2003</year>
        </date>
        <date date-type="updated">
          <day>12</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="revised">
          <day>2</day>
          <month>7</month>
          <year>2009</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="alexander" document-type="chapter">Alexander Disease</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="a-mannosidosis" document-type="chapter">Alpha-Mannosidosis</related-object>
      <abstract id="alkap.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Alkaptonuria is caused by deficiency of homogentisate 1,2-dioxygenase, an enzyme that converts homogentisic acid (HGA) to maleylacetoacetic acid in the tyrosine degradation pathway. The three major features of alkaptonuria are the presence of HGA in the urine, ochronosis (bluish-black pigmentation in connective tissue), and arthritis of the spine and larger joints. Oxidation of the HGA excreted in the urine produces a melanin-like product and causes the urine to turn dark on standing. Ochronosis occurs only after age 30 years; arthritis often begins in the third decade. Other manifestations include pigment deposition, aortic or mitral valve calcification or regurgitation and occasionally aortic dilatation, renal stones, and prostate stones.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of alkaptonuria is based on the detection of a significant amount of HGA in the urine by gas chromatography-mass spectrometry analysis. The amount of HGA excreted per day in individuals with alkaptonuria is usually between one and eight grams. Identification of biallelic pathogenic variants in <italic toggle="yes">HGD</italic> on molecular genetic testing confirms the diagnosis and allows family studies.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Management of joint pain tailored to the individual; physical and occupational therapy to help maintain muscle strength and flexibility; knee, hip, and shoulder replacements when needed; surgical intervention for prostate stones and renal stones as needed; aortic stenosis may necessitate valve replacement.</p>
          <p><italic toggle="yes">Surveillance:</italic> In individuals older than age 40 years, echocardiography to detect aortic dilation, aortic or mitral valve calcification, and stenosis; CT to detect coronary artery calcification.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Physical stress to the spine and large joints, including heavy manual labor or high-impact sports, to try to reduce progression of severe arthritis.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Testing for the presence of elevated urinary HGA in sibs of affected individuals allows for early diagnosis and intervention to prevent secondary complications.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Alkaptonuria is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if both <italic toggle="yes">HGD</italic> pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="alkap.Diagnosis">
        <title>Diagnosis</title>
        <sec id="alkap.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Alkaptonuria <bold>should be suspected</bold> in individuals with any of the following major features:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Dark urine or urine that turns dark on standing.</bold> Oxidation of homogentisic acid (HGA) excreted in the urine produces a melanin-like product and causes the urine to turn dark on standing. Individuals with alkaptonuria usually have dark urine or urine that turns dark on standing or exposure to an alkaline agent. However, darkening may not occur for several hours after voiding and many individuals never observe any abnormal color to their urine.</p>
            </list-item>
            <list-item>
              <p><bold>Ochronosis</bold>
<bold>(bluish-black pigmentation of connective tissue).</bold> Accumulation of HGA and its oxidation products (e.g., benzoquinone acetic acid) in connective tissue leads to ochronosis (<xref ref-type="fig" rid="alkap.F1">Figure 1</xref>).</p>
              <list list-type="bullet">
                <list-item>
                  <p>Brown pigmentation of the sclera is observed midway between the cornea and the outer and inner canthi at the insertion of the recti muscles. Pigment deposition may also be seen in the conjunctiva and cornea. The pigmentation does not affect vision [<xref ref-type="bibr" rid="alkap.REF.ch_vez_barrios.2004.1060">Ch&#x000e9;vez Barrios &#x00026; Font 2004</xref>].</p>
                </list-item>
                <list-item>
                  <p>Ear cartilage pigmentation is seen in the concha and antihelix. The cartilage is slate blue or gray and feels irregular or thickened. Calcification of the ear cartilage may be observed on radiographs.</p>
                </list-item>
                <list-item>
                  <p>Pigment also appears in cerumen and in perspiration, causing discoloration of clothing.</p>
                </list-item>
                <list-item>
                  <p>A deep purple or black discoloration may be seen on the skin of the hands, corresponding to the underlying tendons, or in the web between the thumb and index finger.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Arthritis,</bold> often beginning in the spine and resembling ankylosing spondylitis in its large-joint distribution. Radiographs of the spine showing flattened and calcified intervertebral disks are pathognomonic (<xref ref-type="fig" rid="alkap.F1">Figure 1</xref>). Findings include degeneration of the intervertebral disks followed by disk calcification and eventually fusion of the vertebral bodies. Osteophyte formation and calcification of the intervertebral ligaments also occur. Radiographs of the large joints may show joint space narrowing, subchondral cysts, and osteophyte formation. Enthesopathy can be seen at the muscle insertions [<xref ref-type="bibr" rid="alkap.REF.mannoni.2004.239">Mannoni et al 2004</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="alkap.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of alkaptonuria <bold>is established</bold> in a proband with the following:</p>
          <sec id="alkap.Biochemical_Findings">
            <title>Biochemical Findings</title>
            <p><bold>Elevated homogentisic acid (HGA) in the urine.</bold> The diagnosis of alkaptonuria is based on the detection of a significant amount of HGA in a urine sample by gas chromatography-mass spectrometry analysis. The amount of HGA excreted per day in individuals with alkaptonuria is usually between one and eight grams. A normal 24-hour urine sample contains 20-30 mg of HGA.</p>
            <p>Notes: (1) Elevated HGA can be detected on a random urine sample. (2) Biochemical testing cannot detect the carrier state.</p>
          </sec>
          <sec id="alkap.Molecular_Genetic_Findings">
            <title>Molecular Genetic Findings</title>
            <p>Identification of biallelic pathogenic variants in <italic toggle="yes">HGD</italic> on molecular genetic testing (see <xref ref-type="table" rid="alkap.T.molecular_genetic_testing_used_i">Table 1</xref>) is not required to establish the diagnosis in a proband. However, molecular genetic testing is needed in order to provide carrier testing and prenatal test result interpretation for at-risk family members.</p>
            <p>Molecular testing approaches can include <bold>single-gene testing</bold> and <bold>genome sequencing.</bold></p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">HGD</italic> is performed first, followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
                <p>Note: Targeted analysis for pathogenic variants may be performed first in individuals of Slovak ancestry. Pathogenic variants included in a panel may vary by laboratory.</p>
              </list-item>
              <list-item>
                <p><bold>Comprehensive genome sequencing</bold> (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of alkaptonuria. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
              </list-item>
            </list>
            <table-wrap id="alkap.T.molecular_genetic_testing_used_i" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in Alkaptonuria</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">HGD</italic>
                    </td>
                    <td headers="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">90%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2 individuals&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants</td>
                    <td headers="hd_h_alkap.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;80%&#x000a0;<sup>6</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="alkap.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="alkap" object-id="alkap.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="alkap.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="alkap.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="alkap.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice-site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="alkap.TF.1.4">
                  <label>4. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="alkap.TF.1.5">
                  <label>5. </label>
                  <p>To date, only two individuals with deletions involving <italic toggle="yes">HGD</italic> have been reported [<xref ref-type="bibr" rid="alkap.REF.zouheir_habbal.2014.e106948">Zouheir Habbal et al 2014</xref>, <xref ref-type="bibr" rid="alkap.REF.nemethova.2016.66">Nemethova et al 2016</xref>].</p>
                </fn>
                <fn id="alkap.TF.1.6">
                  <label>6. </label>
                  <p>Four pathogenic variants (<xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.481G&#x0003e;A</xref>, <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.457dup</xref>, <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.808G&#x0003e;A</xref>, and <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.1111dup</xref>) represent Slovak founder variants, accounting for 80% of all pathogenic variants found in the Slovak population. Six pathogenic variants <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.688C&#x0003e;T</xref>, <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.899T&#x0003e;G</xref>, <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.174delA</xref>, <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.16-1G&#x0003e;A</xref>, <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.342+1G&#x0003e;A</xref>, and <xref ref-type="table" rid="alkap.T.selected_hgd_pathogenic_variants">c.140C&#x0003e;T</xref> are common in other populations, but rare in the Slovak population.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="alkap.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="alkap.Clinical_Description">
          <title>Clinical Description</title>
          <p>The clinical findings of alkaptonuria include darkening of urine on standing as a result of the presence of homogentisic acid (HGA) and its oxidation products, connective tissue ochronosis, and arthritis of the spine and larger joints. HGA excretion and disease severity can vary significantly within the same family. In some individuals, the diagnosis of alkaptonuria is identified only after the individual seeks medical attention for chronic joint pain or after black articular cartilage is noted during orthopedic surgery.</p>
          <p>Alkaptonuria does not cause developmental delay or cognitive impairment and does not generally reduce the life span of affected individuals.</p>
          <p><bold>Urinary changes.</bold> Individuals with alkaptonuria usually have dark urine or urine that turns dark on standing or exposure to an alkaline agent. However, darkening may not occur for several hours after voiding and many individuals never observe any abnormal color to their urine.</p>
          <p><bold>Connective tissue.</bold> In general, pigmentary changes are observed after age 30 years. Tendon-related findings, including a thickened Achilles tendon, tendonitis, and rupture, have also been observed clinically [<xref ref-type="bibr" rid="alkap.REF.phornphutkul.2002.2111">Phornphutkul et al 2002</xref>] and are demonstrable by MRI.</p>
          <p><bold>Joints.</bold> Ochronotic arthritis is a regular manifestation of longstanding alkaptonuria. Joint symptoms involving the spine usually appear in the third decade. In one large series, low back pain was observed prior to age 30 years in 49% of individuals and prior to age 40 years in 94% [<xref ref-type="bibr" rid="alkap.REF.phornphutkul.2002.2111">Phornphutkul et al 2002</xref>].</p>
          <p>Lumbar and thoracic spine symptoms precede cervical spine symptoms. The sacroiliac region is usually spared. Limitation of spine flexion directly correlates with degree of disability. Individuals with decreased forward flexion demonstrate impaired function and increased fatigue [<xref ref-type="bibr" rid="alkap.REF.perry.2006.2280">Perry et al 2006</xref>].</p>
          <p>Joint disease appears to start earlier and progress more rapidly in males than in females. Knees, hips, and shoulders are frequently affected. Fifty percent of individuals require at least one joint replacement by age 55 years [<xref ref-type="bibr" rid="alkap.REF.phornphutkul.2002.2111">Phornphutkul et al 2002</xref>]. Small joint involvement is not significant.</p>
          <p>Because the kidneys are responsible for secreting massive quantities of HGA, impaired renal function can accelerate the development of ochronosis and joint destruction [<xref ref-type="bibr" rid="alkap.REF.introne.2002.136">Introne et al 2002</xref>].</p>
          <p>
            <bold>Other organ involvement</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Heart.</bold> Pigment deposition in the heart valves and blood vessels leads to aortic or mitral valve calcification with stenosis or regurgitation and occasionally aortic dilatation. Aortic valve stenosis occurs at a high frequency in the sixth and seventh decades of life. Unlike cardiac valve disease that occurs in the general population, there is no correlation with standard cardiovascular risk factors. Aortic stenosis may necessitate aortic valve replacement. Coronary artery calcification has been demonstrated on chest CT [<xref ref-type="bibr" rid="alkap.REF.hannoush.2012.198">Hannoush et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Renal stones.</bold> By age 64 years, 50% of individuals with alkaptonuria have a history of renal stones.</p>
            </list-item>
            <list-item>
              <p><bold>Prostate stones.</bold> Black prostate stones occur relatively frequently in individuals with alkaptonuria. In one series, eight of 27 men age 31-60 years had prostate stones. Prostate stones may contribute to recurrent infection or urinary obstruction and require surgical removal.</p>
            </list-item>
          </list>
        </sec>
        <sec id="alkap.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No correlation is observed between the type of <italic toggle="yes">HGD</italic> pathogenic variant and amount of HGA excreted or disease severity.</p>
        </sec>
        <sec id="alkap.Penetrance">
          <title>Penetrance</title>
          <p>Elevated urinary HGA and ochronotic arthritis occur in all individuals who are homozygous or compound heterozygous for pathogenic variants in <italic toggle="yes">HGD</italic>.</p>
        </sec>
        <sec id="alkap.Nomenclature">
          <title>Nomenclature</title>
          <p>Occasionally alkaptonuria is referred to collectively (and incorrectly) as ochronosis.</p>
        </sec>
        <sec id="alkap.Prevalence">
          <title>Prevalence</title>
          <p>At least 1000 affected individuals have been described in the literature; this is likely an underestimate. The incidence of alkaptonuria in the US is estimated at 1:250,000 to 1:1,000,000 live births.</p>
          <p>Alkaptonuria occurs worldwide; a high prevalence has been observed in the Dominican Republic and in northwestern Slovakia, likely as the result of a founder effect. The prevalence of alkaptonuria in Slovakia is estimated at 1:19,000 [<xref ref-type="bibr" rid="alkap.REF.zatkova.2003.145">Zatkova et al 2003</xref>].</p>
        </sec>
      </sec>
      <sec id="alkap.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are associated with pathogenic variants in <italic toggle="yes">HGD</italic>.</p>
      </sec>
      <sec id="alkap.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Ochronosis.</bold> Ochronosis resulting from alkaptonuria may be confused with acquired, reversible pigmentary changes following prolonged use of carbolic acid dressings for chronic cutaneous ulcers [<xref ref-type="bibr" rid="alkap.REF.la_du.2001">La Du 2001</xref>]. Chemically induced ochronosis has also been described following long-term use of either the antimalarial agent Atabrine<sup>&#x000ae;</sup> [<xref ref-type="bibr" rid="alkap.REF.ludwig.1963.378">Ludwig et al 1963</xref>], the skin-lightening agent hydroquinone, or the antibiotic minocycline [<xref ref-type="bibr" rid="alkap.REF.suwannarat.2004.3698">Suwannarat et al 2004</xref>].</p>
        <p>In one individual with alkaptonuria, the ochronotic pigment in the eye was misdiagnosed as melanosarcoma, resulting in enucleation of the eye [<xref ref-type="bibr" rid="alkap.REF.skinsnes.1948.552">Skinsnes 1948</xref>].</p>
        <p>A thorough history combined with lack of excessive HGA excretion in the urine should eliminate false positive diagnoses.</p>
        <p><bold>Arthritis.</bold> The arthritis of alkaptonuria resembles ankylosing spondylitis in its damage to the spine and large joints, although it differs in sparing the sacroiliac joint and in its radiographic appearance. Radiographic findings of the spine also differentiate alkaptonuria from rheumatoid arthritis and osteoarthritis.</p>
      </sec>
      <sec id="alkap.Management">
        <title>Management</title>
        <sec id="alkap.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with alkaptonuria, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete history and physical examination with particular attention to range of motion in the spine and large joints</p>
            </list-item>
            <list-item>
              <p>Physical medicine and rehabilitation evaluation if limited range of motion or joint pain occurs</p>
            </list-item>
            <list-item>
              <p>Electrocardiogram and echocardiogram in individuals older than age 40 years</p>
            </list-item>
            <list-item>
              <p>Renal ultrasound examination or helical abdominal CT to evaluate for the presence of renal calculi</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="alkap.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Joint pain is substantial in individuals with alkaptonuria, and close attention to pain control is necessary. Optimal pain management should be tailored to the individual with close follow up and long-term management.</p>
          <p>Physical and occupational therapy are important to promote optimal muscle strength and flexibility.</p>
          <p>Knee, hip, and shoulder replacement surgeries are options for managing significant arthritis. In general, the goal of joint replacement is pain relief rather than increased range of motion. Joint replacement in individuals with alkaptonuria is associated with prosthetic survival comparable to that found in individuals with osteoarthritis [<xref ref-type="bibr" rid="alkap.REF.spencer.2004.355">Spencer et al 2004</xref>].</p>
          <p>Aortic stenosis may necessitate valve replacement.</p>
          <p>Treatment of prostate stones and renal stones may include surgical intervention.</p>
        </sec>
        <sec id="alkap.Prevention_of_Primary_Manifestatio">
          <title>Prevention of Primary Manifestations</title>
          <p>Although several therapeutic modalities have been investigated, no preventive or curative treatment is available. See <xref ref-type="sec" rid="alkap.Therapies_Under_Investigation">Therapies Under Investigation</xref>.</p>
        </sec>
        <sec id="alkap.Prevention_of_Secondary_Manifestat">
          <title>Prevention of Secondary Manifestations</title>
          <p>Maintaining joint range of motion through moderate non-weight-bearing exercise such as swimming may have beneficial effects.</p>
          <p>Younger individuals with alkaptonuria should be directed toward non-contact and lower-impact sports.</p>
        </sec>
        <sec id="alkap.Surveillance">
          <title>Surveillance</title>
          <p><bold>Cardiac.</bold> Surveillance for cardiac complications every one to two years is advisable after age 40 years and should include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Echocardiography to detect aortic dilation and aortic or mitral valve calcification and stenosis;</p>
            </list-item>
            <list-item>
              <p>Surveillance CT scans (according to the recommendation of a cardiologist) in affected individuals with coronary artery calcification.</p>
            </list-item>
          </list>
          <p><bold>Urology.</bold> Urologic complications become more prevalent after age 40 years:</p>
          <list list-type="bullet">
            <list-item>
              <p>Routine surveillance is not recommended, but awareness of this potential complication is advised.</p>
            </list-item>
            <list-item>
              <p>Ochronotic prostate stones appear on radiography; kidney stones can be identified by ultrasonography and helical abdominal CT.</p>
            </list-item>
          </list>
        </sec>
        <sec id="alkap.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoidance of physical stress to the spine and large joints, including heavy manual labor or high-impact sports, may reduce the progression of severe arthritis.</p>
        </sec>
        <sec id="alkap.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of a proband in order to identify as early as possible those who would benefit from preventive measures. Those found to have alkaptonuria should be counseled to avoid high-impact and contact sports. Career considerations include avoidance of occupations involving heavy physical labor. Instruction on joint strengthening and flexibility exercises, in conjunction with appropriate physical activity, can help preserve overall joint mobility and function.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Biochemical testing for the presence of elevated urinary homogentisic acid (HGA).</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="alkap.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="alkap.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Pharmacologic treatment of alkaptonuria with oral administration of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) or nitisinone has been proposed [<xref ref-type="bibr" rid="alkap.REF.anikster.1998.920">Anikster et al 1998</xref>]. Nitisinone is a triketone herbicide that inhibits 4-hydroxyphenylpyruvate dioxygenase, the enzyme that produces HGA. Nitisinone is approved for the treatment of <related-object link-type="booklink" source-id="gene" document-id="tyrosinemia" document-type="chapter">tyrosinemia type I</related-object>.</p>
          <p>Nitisinone reduced urinary HGA excretion by at least 69% in two individuals, but at the expense of an elevated plasma tyrosine concentration [<xref ref-type="bibr" rid="alkap.REF.phornphutkul.2002.2111">Phornphutkul et al 2002</xref>], resulting in photophobia. The only other known side effect is (rarely) corneal crystals. Theoretically, neurologic complications associated with tyrosinemia type III may develop.</p>
          <p>In a pilot study, low-dose nitisinone reduced urinary HGA by up to 95% in nine individuals with alkaptonuria. In the same study, seven individuals were treated for up to 15 weeks with nitisinone while receiving normal protein intake; all had elevated plasma tyrosine concentrations. No ophthalmic, neurologic, or severe dermatologic complications were observed. Two individuals had transient elevations in liver transaminase levels that returned to normal after stopping nitisinone [<xref ref-type="bibr" rid="alkap.REF.suwannarat.2005.719">Suwannarat et al 2005</xref>].</p>
          <p>In a three-year therapeutic trial, 2 mg of nitisinone daily reduced urine and plasma HGA by 95% throughout the study duration [<xref ref-type="bibr" rid="alkap.REF.introne.2011.307">Introne et al 2011</xref>]. Plasma tyrosine averaged 800&#x003bc;M without dietary restriction. Side effects were minimal. One affected individual developed corneal crystals that required discontinuation of nitisinone, and one affected individual had elevated liver transaminases. Statistically significant improvement in hip range of motion and measurements of musculoskeletal function were not observed in the treatment group compared to the control group; however there was a positive trend showing slowing of aortic stenosis. Additional trials are currently underway to establish clinical benefit.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="alkap.Other">
          <title>Other</title>
          <p>No therapy is proven to prevent or correct the pigmentary changes of ochronosis.</p>
          <list list-type="bullet">
            <list-item>
              <p>Dietary restriction of phenylalanine and tyrosine has been proposed to reduce the production of HGA, but severe restriction of these amino acids is not practical in the long term and may be dangerous.</p>
            </list-item>
            <list-item>
              <p>High-dose vitamin C decreases urinary benzoquinone acetic acid, a derivative of HGA, but has no effect on HGA excretion [<xref ref-type="bibr" rid="alkap.REF.wolff.1989.140">Wolff et al 1989</xref>]. It has been hypothesized that high-dose ascorbic acid may prevent the deposition of ochronotic pigment, although it does not alter the basic metabolic defect [<xref ref-type="bibr" rid="alkap.REF.wolff.1989.140">Wolff et al 1989</xref>]. No credible studies have demonstrated the clinical efficacy of ascorbic acid [<xref ref-type="bibr" rid="alkap.REF.la_du.2001">La Du 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>Oral bisphosphonate therapy has been suggested to halt the progressive bone loss; however, a prospective study of four affected individuals failed to demonstrate benefit [<xref ref-type="bibr" rid="alkap.REF.aliberti.2007.729">Aliberti et al 2007</xref>].</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="alkap.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="alkap.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Alkaptonuria is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="alkap.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">HGD</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with alkaptonuria are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">HGD</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of an <italic toggle="yes">HGD</italic> pathogenic variant.</p>
        </sec>
        <sec id="alkap.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p><bold>Molecular genetic testing.</bold> Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">HGD</italic> pathogenic variants in the family.</p>
          <p><bold>Biochemical testing.</bold> Biochemical genetic testing is not reliable as a method of carrier detection.</p>
        </sec>
        <sec id="alkap.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="alkap.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="alkap.Prenatal_Testing_and_Preimplantati">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">HGD</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for alkaptonuria are possible.</p>
          <p><bold>Biochemical testing.</bold> In theory, homogentisic acid can be measured in amniotic fluid; however, no studies have been published to confirm the reliability of the test in an affected fetus.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="alkap.Resources">
        <title>Resources</title>
      </sec>
      <sec id="alkap.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">HGD</italic> is 54.3 kb in length and has 14 exons coding for a 1715-bp transcript [<xref ref-type="bibr" rid="alkap.REF.granadino.1997.115">Granadino et al 1997</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="alkap" object-id="alkap.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> At least 130 pathogenic variants in <italic toggle="yes">HGD</italic> have been reported and are found in different allelic combinations [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://hgddatabase.cvtisr.sk/home.php?select_db=HGD">HGD mutation database</ext-link>]. The pathogenic variants are distributed throughout the <italic toggle="yes">HGD</italic> sequence. The majority of pathogenic variants are missense; nonsense, frame shift, and splice-site variants also occur.</p>
        <list list-type="bullet">
          <list-item>
            <p>p.Cys120Trp is a founder variant in the Dominican Republic [<xref ref-type="bibr" rid="alkap.REF.goicoechea_de_jorge.2002.e40">Goicoechea De Jorge et al 2002</xref>].</p>
          </list-item>
          <list-item>
            <p>In the Slovak population, evidence exists for mutational hot spots (e.g., c.342+1G&#x0003e;A [<xref ref-type="bibr" rid="alkap.REF.zatkov_.2000.1333">Zatkov&#x000e1; et al 2000</xref>]) and a founder effect (e.g., the frequent pathogenic variant p.Gly161Arg [<xref ref-type="bibr" rid="alkap.REF.srsen.2002.353">Srsen et al 2002</xref>]).</p>
          </list-item>
          <list-item>
            <p>The most prevalent pathogenic variant in Europe (excluding the Slovak population) is c.1102A&#x0003e;G (p.Met368Val).</p>
          </list-item>
          <list-item>
            <p>No mutational hot spot or founder effect has been identified in the US [<xref ref-type="bibr" rid="alkap.REF.phornphutkul.2002.2111">Phornphutkul et al 2002</xref>].</p>
          </list-item>
        </list>
        <table-wrap id="alkap.T.selected_hgd_pathogenic_variants" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">HGD</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change&#x02019;(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.140C&#x0003e;T</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser47Leu</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_3" rowspan="12" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000187.3">NM_000187.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000178.2">NP_000178.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.16-1G&#x0003e;A<break/>(IVS1-1G&#x0003e;A)</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr6_Gln29del</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.174delA</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser59AlafsTer52<break/>(Ser59AlafsTer31) (R58fs)</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.360T&#x0003e;G</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys120Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.342+1G&#x0003e;A<break/>(IVS5+1G&#x0003e;A)</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu95_Ser114del</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.457dup</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp153GlyfsTer26<break/>(Gly152fs)</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.481G&#x0003e;A</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly161Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.688C&#x0003e;T</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro230Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.808G&#x0003e;A</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly270Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.899T&#x0003e;G</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val300Gly</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1102A&#x0003e;G</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met368Val</td>
              </tr>
              <tr>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1111dup<break/>(111_1112insC)</td>
                <td headers="hd_h_alkap.T.selected_hgd_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His371ProfsTer4<break/>(Pro370fs)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="alkap.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The protein product of <italic toggle="yes">HGD</italic> is homogentisate 1,2-dioxygenase, an enzyme in the phenylalanine and tyrosine degradation pathway (see <xref ref-type="fig" rid="alkap.F2">Figure 2</xref>). The enzyme is composed of 445 amino acids and is expressed predominantly in the liver and kidney, with some expression in the small intestine, colon, and prostate [<xref ref-type="bibr" rid="alkap.REF.fern_ndezca__n.1996.19">Fern&#x000e1;ndez-Ca&#x000f1;&#x000f3;n et al 1996</xref>]. Homogentisate 1,2-dioxygenase functions in the metabolism of HGA by catalyzing an oxidative cleavage of the benzene ring to yield maleylacetoacetic acid. It requires oxygen, ferrous iron, and sulfhydryl groups.</p>
        <p><bold>Abnormal gene product.</bold> Most mutated <italic toggle="yes">HGD</italic> alleles are predicted to result in complete loss of enzymatic activity.</p>
      </sec>
      <sec id="alkap.References">
        <title>References</title>
        <sec id="alkap.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="alkap.Literature_Cited.reflist0">
            <ref id="alkap.REF.aliberti.2007.729">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aliberti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulignano</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pisani</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocchietti March</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Porto</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proietta</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Bisphosphonate treatment in ochronotic osteoporotic patients.</article-title>
                <source>Clin Rheumatol</source>
                <volume>26</volume>
                <fpage>729</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">16924393</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.anikster.1998.920">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nyhan</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>NTBC and alkaptonuria.</article-title>
                <source>Am J Hum Genet</source>
                <volume>63</volume>
                <fpage>920</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">9718357</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.ch_vez_barrios.2004.1060">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ch&#x000e9;vez Barrios</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <article-title>Pigmented conjunctival lesions as initial manifestation of ochronosis.</article-title>
                <source>Arch Ophthalmol.</source>
                <year>2004</year>
                <month>Jul</month>
                <volume>122</volume>
                <issue>7</issue>
                <fpage>1060</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15249376</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.fern_ndezca__n.1996.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez-Ca&#x000f1;&#x000f3;n</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Granadino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beltr&#x000e1;n-Valero de Bernab&#x000e9;</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renedo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fern&#x000e1;ndez-Ruiz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pe&#x000f1;alva</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez de C&#x000f3;rdoba</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>The molecular basis of alkaptonuria.</article-title>
                <source>Nat Genet.</source>
                <year>1996</year>
                <month>Sep</month>
                <volume>14</volume>
                <issue>1</issue>
                <fpage>19</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">8782815</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.goicoechea_de_jorge.2002.e40">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goicoechea De Jorge</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallardo</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Per&#x000e9;z De Ferr&#x000e1;n</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendoza</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez De C&#x000f3;rdoba</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Alkaptonuria in the Dominican Republic: identification of the founder AKU mutation and further evidence of mutation hot spots in the HGO gene.</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>E40</fpage>
                <pub-id pub-id-type="pmid">12114497</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.granadino.1997.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Granadino</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beltran-Valero de Bernabe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez-Canon</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penalva</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez de Cordoba</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>The human homogentisate 1,2-dioxygenase (HGO) gene.</article-title>
                <source>Genomics</source>
                <volume>43</volume>
                <fpage>115</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">9244427</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.hannoush.2012.198">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hannoush</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Introne</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>S-J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O&#x02019;Brien</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suwannarat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kayser</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachdev</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Aortic stenosis and vascular calcifications in alkaptonuria.</article-title>
                <source>Mol Genet Metab</source>
                <volume>105</volume>
                <fpage>198</fpage>
                <lpage>202</lpage>
                <pub-id pub-id-type="pmid">22100375</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.introne.2011.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Introne</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Troendle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsilou</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kayser</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suwannarat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachdev</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reynolds</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moylan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <article-title>A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2011</year>
                <volume>103</volume>
                <fpage>307</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">21620748</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.introne.2002.136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Introne</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phornphutkul</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaughlin</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzpatrick</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation.</article-title>
                <source>Mol Genet Metab</source>
                <volume>77</volume>
                <fpage>136</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">12359141</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.la_du.2001">
              <mixed-citation publication-type="book">La Du BN. Alkaptonuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease.</italic> 8 ed. New York, NY: McGraw-Hill; 2001:2109-23.</mixed-citation>
            </ref>
            <ref id="alkap.REF.ludwig.1963.378">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ludwig</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toole</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>1963</year>
                <article-title>Ochronosis from quinacrine (atabrine).</article-title>
                <source>Ann Intern Med</source>
                <volume>59</volume>
                <fpage>378</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">14065956</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.mannoni.2004.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mannoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Selvi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenzini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giorgi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Airo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cammelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreotti</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcolongo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porfirio</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Alkaptonuria, ochronosis, and ochronotic arthropathy.</article-title>
                <source>Semin Arthritis Rheum</source>
                <volume>33</volume>
                <fpage>239</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">14978662</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.nemethova.2016.66">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nemethova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radvanszky</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadasi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ascher</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pires</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blundell</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porfirio</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santucci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milucci</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sestini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biolcati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorge</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aurizi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aquaron</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alsbou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Louren&#x000e7;o</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramadevi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranganath</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Kan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sireau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayoob</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmis</surname>
                    <given-names>OG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sang</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genovese</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imrich</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rovensky</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srinivasaraghavan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bharadwaj</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiegel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zatkova</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/25804398">Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on 'black bone disease' in Italy.</ext-link>
                <source>Eur J Hum Genet.</source>
                <year>2016</year>
                <volume>24</volume>
                <fpage>66</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">25804398</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.perry.2006.2280">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suwannarat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furst</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerber</surname>
                    <given-names>LH</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Musculoskeletal findings and disability in alkaptonuria.</article-title>
                <source>J Rheumatol</source>
                <volume>33</volume>
                <fpage>2280</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16981292</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.phornphutkul.2002.2111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Phornphutkul</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Introne</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphey</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzpatrick</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huizing</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerber</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Natural history of alkaptonuria.</article-title>
                <source>N Engl J Med</source>
                <volume>347</volume>
                <fpage>2111</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">12501223</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.skinsnes.1948.552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Skinsnes</surname>
                    <given-names>OK</given-names>
                  </name>
                </person-group>
                <year>1948</year>
                <article-title>Generalized ochronosis; report of an instance in which it was misdiagnosed as melanosarcoma, with resultant enucleation of an eye.</article-title>
                <source>Arch Pathol (Chic)</source>
                <volume>45</volume>
                <fpage>552</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18891026</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.spencer.2004.355">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbons</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharp</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carr</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Athanasou</surname>
                    <given-names>NA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Arthroplasty for ochronotic arthritis: no failure of 11 replacements in 3 patients followed 6-12 years.</article-title>
                <source>Acta Orthop Scand</source>
                <volume>75</volume>
                <fpage>355</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15260431</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.srsen.2002.353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Srsen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fregin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srsnova</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Alkaptonuria in Slovakia: thirty-two years of research on phenotype and genotype.</article-title>
                <source>Mol Genet Metab</source>
                <volume>75</volume>
                <fpage>353</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12051967</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.suwannarat.2005.719">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Suwannarat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebring</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaiser-Kupfer</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubin</surname>
                    <given-names>BI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsilou</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerber</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Use of nitisinone in patients with alkaptonuria.</article-title>
                <source>Metabolism</source>
                <volume>54</volume>
                <fpage>719</fpage>
                <lpage>28</lpage>
                <pub-id pub-id-type="pmid">15931605</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.suwannarat.2004.3698">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Suwannarat</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phornphutkul</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Minocycline-induced hyperpigmentation masquerading as alkaptonuria in individuals with joint pain.</article-title>
                <source>Arthritis Rheum</source>
                <volume>50</volume>
                <fpage>3698</fpage>
                <lpage>701</lpage>
                <pub-id pub-id-type="pmid">15529343</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.wolff.1989.140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wolff</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nyhan</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leslie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seegmiller</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruber</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garst</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michals</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy.</article-title>
                <source>Pediatr Res</source>
                <volume>26</volume>
                <fpage>140</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">2771520</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.zatkova.2003.145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zatkova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chmelikova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polakova</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferakova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadasi</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Rapid detection methods for five HGO gene mutations causing alkaptonuria.</article-title>
                <source>Clin Genet</source>
                <volume>63</volume>
                <fpage>145</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12630963</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.zatkov_.2000.1333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zatkov&#x000e1;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Bernab&#x000e9;</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pol&#x000e1;kov&#x000e1;</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zvar&#x000ed;k</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fer&#x000e1;kov&#x000e1;</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bos&#x000e1;k</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fer&#x000e1;k</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000e1;dasi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de C&#x000f3;rdoba</surname>
                    <given-names>SR</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>High frequency of alkaptonuria in Slovakia: evidence for the appearance of multiple mutations in HGO involving different mutational hot spots.</article-title>
                <source>Am J Hum Genet</source>
                <volume>67</volume>
                <fpage>1333</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11017803</pub-id>
              </element-citation>
            </ref>
            <ref id="alkap.REF.zouheir_habbal.2014.e106948">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zouheir Habbal</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bou-Assi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Owen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chehab</surname>
                    <given-names>FF</given-names>
                  </name>
                </person-group>
                <article-title>First report of a deletion encompassing an entire exon in the homogentisate 1,2-dioxygenase gene causing alkaptonuria.</article-title>
                <source>PLoS One.</source>
                <year>2014</year>
                <volume>9</volume>
                <fpage>e106948</fpage>
                <pub-id pub-id-type="pmid">25233259</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="alkap.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="alkap.Author_Notes">
          <title>Author Notes</title>
          <p>Dr. Introne is a pediatrician, clinical geneticist, and biochemical geneticist.</p>
          <p>Dr. Gahl is a pediatrician, clinical geneticist, and biochemical geneticist who performs clinical and basic research into rare diseases.</p>
        </sec>
        <sec id="alkap.Author_History">
          <title>Author History</title>
          <p>William A Gahl, MD, PhD (2003-present) Wendy J Introne, MD (2003-present) Michael A Kayser, DO; Saint Francis Hospital, Tulsa (2007-2013) Chanika Phornphutkul, MD; Brown University (2003-2007) Pim Suwannarat, MD; Mahidol University (2003-2007)</p>
        </sec>
        <sec id="alkap.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>12 May 2016 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 August 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>10 March 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>2 July 2009 (cd) Revision: sequence analysis available clinically</p>
            </list-item>
            <list-item>
              <p>4 December 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>26 June 2006 (ca) Revision: targeted mutation analysis available for eight mutations</p>
            </list-item>
            <list-item>
              <p>24 May 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>9 May 2003 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>4 March 2003 (ps) Original submission</p>
            </list-item>
          </list>
          <p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <italic toggle="yes">GeneReview</italic> &#x02018;Alkaptonuria&#x02019; is in the public domain in the United States of America.</p>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="alkap.F1" orientation="portrait">
          <label>Figure 1<break/></label>
          <caption>
            <p>A. Ochronosis of the sclera of the eyeB. Ochronosis of the antihelix and conchaC. Classic radiographic findings of the lumbar spine with disc flattening, calcification, and osteophyte formation</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="alkap-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="alkap.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>The tyrosine degradation pathway. Alkaptonuria is characterized by deficiency of homogentisate 1,2-dioxygenase, which converts homogentisic acid (HGA) to maleylacetoacetic acid.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="alkap-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
